Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Otto, Caitlin C.; Kaplan, Samuel E.; Stiles, Jeffrey; Mikhlina, Albina; Lee, Cindy; Babady, N. Esther; Tang, Yi‐Wei

doi:10.3791/54312

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Alere i Influenza A & B assay, which is performed on the Alere i instrument, incorporates the Nicking Enzyme Amplification Reaction (NEAR) technique to detect and differentiate influenza viruses A and B [27,28]. Based on the NEAR technique, the templates are designed to target the Flu A-specific PB2 segment and the Flu B-specific PA segment.…”

Section: General Principles and Methodsmentioning

confidence: 99%

Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test

Wang

Deng

Tang

2018

Expert Review of Molecular Diagnostics

Self Cite

View full text Add to dashboard Cite

The Alere i Influenza A & B assay incorporates the Nicking Enzyme Amplification Reaction technique on the Alere i instrument to detect and differentiate influenza virus (Flu) A and B nucleic acids in specific specimens. Areas covered: The Alere i Influenza A & B assay was cleared by the US Food and Drug Administration for use with nasal swabs (NS) and nasopharyngeal swabs, either directly or in viral transport medium. Notably, direct use on NS was the first ever CLIA-waived nucleic acid-based test. Previously published evaluations have reported sensitivities and specificities of 55.2-100% and 62.5-100% for Flu A and 45.2-100% and 53.6-100% for Flu B, respectively. Expert commentary: The Alere i Influenza A & B assay provides a rapid and simple platform for detection and differentiation of Flu A and B. Efforts are expected to further improve sensitivity and user-friendliness for effective and widespread use in the true point-of-care setting.

show abstract

Section: General Principles and Methodsmentioning

confidence: 99%

Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test

Wang

Deng

Tang

2018

Expert Review of Molecular Diagnostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Despite the significant number of researchers working on influenza prevention, the death rate is still high. Thus rapid diagnostic approaches may be the solution [ 53 ]. Up until now, a wide range of tests with different sensitivity, selectivity, cost, and ease of use have been designed.…”

Section: Selective Adhesion On Fet For Biosensing Applicationsmentioning

confidence: 99%

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Sadighbayan

Hasanzadeh

Ghafar-Zadeh

2020

TrAC Trends in Analytical Chemistry

206

View full text Add to dashboard Cite

The use of field-Effect-Transistor (FET) type biosensing arrangements has been highlighted by researchers in the field of early biomarker detection and drug screening. Their non-metalized gate dielectrics that are exposed to an electrolyte solution cover the semiconductor material and actively transduce the biological changes on the surface. The efficiency of these novel devices in detecting different biomolecular analytes in a real-time, highly precise, specific, and label-free manner has been validated by numerous research studies. Considerable progress has been attained in designing FET devices, especially for biomedical diagnosis and cell-based assays in the past few decades. The exceptional electronic properties, compactness, and scalability of these novel tools are very desirable for designing rapid, label-free, and mass detection of biomolecules. With the incorporation of nanotechnology, the performance of biosensors based on FET boosts significantly, particularly, employment of nanomaterials such as graphene, metal nanoparticles, single and multi-walled carbon nanotubes, nanorods, and nanowires. Besides, their commercial availability, and high-quality production on a large-scale, turn them to be one of the most preferred sensing and screening platforms. This review presents the basic structural setup and working principle of different types of FET devices. We also focused on the latest progression regarding the use of FET biosensors for the recognition of viruses such as, recently emerged COVID-19, Influenza, Hepatitis B Virus, protein biomarkers, nucleic acids, bacteria, cells, and various ions. Additionally, an outline of the development of FET sensors for investigations related to drug development and the cellular investigation is also presented. Some technical strategies for enhancing the sensitivity and selectivity of detection in these devices are addressed as well. However, there are still certain challenges which are remained unaddressed concerning the performance and clinical use of transistor-based point-of-care (POC) instruments; accordingly, expectations about their future improvement for biosensing and cellular studies are argued at the end of this review.

show abstract

Point of care molecular and antigen detection tests for COVID-19: current status and future prospects

Stokes

Berenger

Venner

et al. 2022

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Cited by 5 publications

References 25 publications

Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test

Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test

Biosensing based on field-effect transistors (FET): Recent progress and challenges

Point of care molecular and antigen detection tests for COVID-19: current status and future prospects

Contact Info

Product

Resources

About